Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 27

Sort by

Sort Order Select

Journal Articles

Integrated DNA/RNA Profiling for Somatic Alterations in Adult B-Cell ALL

Blood (2015) 126 (23): 1422.

https://doi.org/10.1182/blood.V126.23.1422.1422

Published: 2015

Journal Articles

ETV6 Is An Early T-Cell Progenitor (ETP) Specific Tumor Suppressor Gene in Adult T-ALL

Pieter Van Vlierberghe, PhD, Alberto Ambesi, PhD, Isaura Rigo, Elisabeth Paietta, PhD, Janis Racevskis, PhD, Peter H. Wiernik, MD, Jacob M. Rowe, MD, Montserrat Rue, Adolfo A. Ferrando, MD, PhD

Blood (2011) 118 (21): 406.

https://doi.org/10.1182/blood.V118.21.406.406

Published: 2011

Journal Articles

Single-Agent Rituximab in Treatment-Refractory or Poor Prognosis Patients with Chronic Lymphocytic Leukemia.

Giridhar U. Adiga, MD, Peter H. Wiernik, MD

Blood (2009) 114 (22): 2380.

https://doi.org/10.1182/blood.V114.22.2380.2380

Published: 2009

Journal Articles

Standard Consolidation/Maintenance Chemotherapy Is Consistently Superior to a Single Autologous Transplant for Adult Patients with Acute Lymphoblastic Leukemia: Results of the International ALL Trial (MRC UKALL XII/ECOG E2993)

Jacob M. Rowe, MD, Georgina Buck, Anthony V Moorman, MD, Martin S Tallman, MD, Susan M Richards, Ph.D, Adele K Fielding, MD, Ph.D, Alan K. Burnett, MD, FRCP, Ian M Franklin, MD, Peter H. Wiernik, MD, Hillard M Lazarus, MD, Elisabeth Paietta, PhD, Mark R. Litzow, MD, David I Marks, MD, Selina Luger, MD, Gordon W. Dewald, PhD, PhD, FACMG, Anthony H. Goldstone, FRCP, FRCPath

Blood (2008) 112 (11): 3314.

https://doi.org/10.1182/blood.V112.11.3314.3314

Published: 2008

Journal Articles

Treatment-Related Mortality and Relapse Rate from Time of Initiation of Post-Remission Therapy for Patients Receiving Allogeneic Transplantation, Autologous Transplantation or Intensive Chemotherapy: A Report from the Eastern Cooperative Oncology Group (ECOG)

Jacob M. Rowe, MD, Zhuoxin Sun, Ph.D, Peter A. Cassileth, MD, Frederick R. Appelbaum, MD, Peter H. Wiernik, MD, Hillard M Lazarus, MD, Karl G. Blume, MD, Hugo F. Fernandez, MD, Mark R. Litzow, MD, Martin S Tallman

Blood (2008) 112 (11): 49.

https://doi.org/10.1182/blood.V112.11.49.49

Published: 2008

Journal Articles

Implications for the Use of Monoclonal Antibodies in Future Adult ALL Trials: Analysis of Antigen Expression in 505 B-Lineage (B-Lin) ALL Patients (pts) on the MRC UKALLXII/ECOG2993 Intergroup Trial.

Elisabeth Paietta, Ph.D., Xiaochun Li, Ph.D., Sue Richards, Janis Racevskis, Ph.D., Gordon W. Dewald, PhD, PhD, FACMG, Jacob M. Rowe, MD, Martin S Tallman, Hillard M Lazarus, MD, Mark Litzow, M.D., Anthony H. Goldstone, FRCP, FRCPath, Peter H. Wiernik, MD

Blood (2008) 112 (11): 1907.

https://doi.org/10.1182/blood.V112.11.1907.1907

Published: 2008

Journal Articles

The Pitfalls of Early Publication of Data in Acute Myeloid Leukemia: A Report from the Eastern Cooperative Oncology Group (ECOG).

Jacob M. Rowe, MD, Xiaopan Yao, Ph.D, Peter A. Cassileth, MD, Frederick R. Appelbaum, MD, Peter H. Wiernik, MD, Charles Schiffer, MD, Mark R. Litzow, MD, Selina Luger, MD, John M. Bennett, MD, Hillard M Lazarus, MD, Martin S Tallman

Blood (2008) 112 (11): 1952.

https://doi.org/10.1182/blood.V112.11.1952.1952

Published: 2008

Journal Articles

Treatment Type Determines Gene Expression Changes from Pretreatment (PTx) to Relapse (Rel) in Acute Promyelocytic Leukemia (APL).

Qingping Cui, PhD, Haesook Kim, PhD, Da-Cheng Zhou, MD,PhD, Peter H. Wiernik, MD, Martin S. Tallman, MD, Robert E. Gallagher, MD

Blood (2007) 110 (11): 3167.

https://doi.org/10.1182/blood.V110.11.3167.3167

Published: 2007

Journal Articles

Continued Late Conversion to Complete Remission (CR/CRu) and Durability of Remission (DUR) in Pts with B-Cell Follicular Lymphoma (FL) Treated with Rituximab Followed by Mitumprotimut-T (Id-KLH, FavId®) Active Immunotherapy.

Omer N. Koc, MD, Charles Redfern, MD, Peter H. Wiernik, MD, Fred Rosenfelt, MD, Jane N. Winter, MD, Troy H. Guthrie, MD, Lawrence Kaplan, MD, Peter Holman, MD, John Densmore, MD, PhD, John Hainsworth, MD, Thomas S. Lin, MD, Rene A. Castillo, MD, Nalini Janakiraman, MD, Richard G. Ghalie, MD

Blood (2007) 110 (11): 3427.

https://doi.org/10.1182/blood.V110.11.3427.3427

Published: 2007

Journal Articles

Initial Results from an International Study in Relapsed/Refractory Aggressive Non-Hodgkin’s Lymphoma To Confirm the Activity, Safety and Criteria for Predicting Response to Lenalidomide Monotherapy.

Thomas E. Witzig, MD, Craig B. Reeder, MD, Jonathan Polikoff, MD, Naveed M. Chowhan, MD, Isaac Esseessee, MD, Richard Greenberg, MD, Hermant Patel, MD, Davood Vafai, MD, Peter H. Wiernik, MD, Annette Ervin-Haynes, DO, Dennis Pietronigro, PhD, Jerome B. Zeldis, MD, PhD, Myron Czuczman, MD

Blood (2007) 110 (11): 2572.

https://doi.org/10.1182/blood.V110.11.2572.2572

Published: 2007

Journal Articles

Results from a Phase II Study of Lenalidomide Oral Monotherapy in Relapsed/Refractory Indolent Non-Hodgkin’s Lymphoma.

Thomas E. Witzig, MD, Julie M. Vose, MD, Timothy D. Moore, MD, Craig B. Reeder, MD, Craig E. Cole, MD, Glen Justice, MD, Henry P. Kaplan, MD, Michael Voralia, MD, Dennis Pietronigro, PhD, Kenichi Takeshita, MD, Annette Ervin-Haynes, DO, Jerome B. Zeldis, MD, PhD, Peter H. Wiernik, MD

Blood (2007) 110 (11): 2560.

https://doi.org/10.1182/blood.V110.11.2560.2560

Published: 2007

Journal Articles

Lenalidomide Response in Relapsed/Refractory Diffuse Large B-Cell Non-Hodgkin’s Lymphoma.

Izidore S. Lossos, MD, Peter H. Wiernik, MD, Glen Justice, MD, Joseph M. Tuscano, MD, Craig E. Cole, MD, Julie M. Vose, MD, Dennis Pietronigro, PhD, Kenichi Takeshita, MD, Annette Ervin-Haynes, DO, Jerome B. Zeldis, MD, PhD, Thomas M. Habermann, MD

Blood (2007) 110 (11): 2564.

https://doi.org/10.1182/blood.V110.11.2564.2564

Published: 2007

Journal Articles

Lenalidomide Response in Relapsed/Refractory Aggressive Non-Hodgkin’s Lymphoma Is Related to Tumor Burden and Time from Rituximab Treatment.

Peter H. Wiernik, MD, Izidore S. Lossos, MD, Joseph M. Tuscano, MD, Glen Justice, MD, Julie M. Vose, MD, Craig E. Cole, MD, Kyle McBride, MS, Kenton Wride, Dennis Pietronigro, PhD, Kenichi Takeshita, MD, Annette Ervin-Haynes, DO, Jerome B. Zeldis, MD, PhD, Thomas M. Habermann, MD

Blood (2007) 110 (11): 2565.

https://doi.org/10.1182/blood.V110.11.2565.2565

Published: 2007

Journal Articles

Preliminary Results from a Phase II Study of Lenalidomide Monotherapy in Relapsed/Refractory Aggressive Non-Hodgkin’s Lymphoma.

Peter H. Wiernik, MD, Izidore Lossos, MD, Joseph Tuscano, MD, Glen Justice, MD, Julie M. Vose, MD, Dennis Pietronigro, PhD, Kenichi Takeshita, MD, Annette Ervin-Haynes, DO, Jerome B. Zeldis, MD,PhD, Thomas M. Habermann, MD

Blood (2006) 108 (11): 531.

https://doi.org/10.1182/blood.V108.11.531.531

Published: 2006

Journal Articles

In Adults with Standard-Risk Acute Lymphoblastic Leukemia (ALL) the Greatest Benefit Is Achieved from an Allogeneic Transplant in First Complete Remission (CR) and an Autologous Transplant Is Less Effective Than Conventional Consolidation/Maintenance Chemotherapy: Final Results of the International ALL Trial (MRC UKALL XII/ECOG E2993).

Jacob M. Rowe, MD, Georgina Buck, PhD, Adele Fielding, MD, Martin S. Tallman, MD, Alan K. Burnett, MD, Raj Chopra, MD, Peter H. Wiernik, MD, Susan M. Richards, PhD, Hillard M. Lazarus, MD, Letizia Foroni, MD, Elisabeth Paietta, PhD, Mark R. Litzow, MD, David Marks, MD, Jill Durrant, MD, Anthony H. Goldstone, MD

Blood (2006) 108 (11): 2.

https://doi.org/10.1182/blood.V108.11.2.2

Published: 2006

Journal Articles

KLHDC8B Is a Novel, Mitotically-Regulated Classical Hodgkin’s Lymphoma Candidate Susceptibility Gene.

Mathew E. Mealiffe, MD, Tomas Kirchhoff, PhD, Peter H. Wiernik, MD, Henry T. Lynch, MD, Masanori Daibata, MD,PhD, Anne-Marie Gerdes, MD, Kenneth Offit, MD, Lynn R. Goldin, PhD, Marshall S. Horwitz, MD,PhD

Blood (2006) 108 (11): 473.

https://doi.org/10.1182/blood.V108.11.473.473

Published: 2006

Journal Articles

Common Gene Expression Changes in Matched Pretreatment and Relapse Samples from Eastern Cooperative Oncology Group Acute Promyelocytic Leukemia (APL) Patients Treated on the Chemotherapy (C) or All- Trans Retinoic Acid (ATRA)-Containing (A) Randomization Arms of Protocol E2491.

Qingping Cui, PhD, Haesook Kim, PhD, Peter H. Wiernik, MD, Martin S. Tallman, MD, Robert E. Gallagher, MD

Blood (2006) 108 (11): 4311.

https://doi.org/10.1182/blood.V108.11.4311.4311

Published: 2006

Journal Articles

Active Immunotherapy with FavId® (Id/KLH) Following Rituximab Induction: Long-Term Follow-Up of Response Rate Improvement (RRI) and Disease Progression in Follicular Lymphoma Patients (pts).

Omer N. Koc, MD, Charles Redfern, MD, Peter H. Wiernik, MD, Fred Rosenfelt, MD, Jane N. Winter, MD, Troy H. Guthrie, MD, Lawrence Kaplan, MD, Peter Holman, MD, John Densmore, MD, PhD, John Hainsworth, MD, Thomas S. Lin, MD, PhD, Rene A. Castillo, MD, Nalini Janakiraman, MD, Teresa Melink, NP, Song Liu, John Bender, PharmD

Blood (2006) 108 (11): 691.

https://doi.org/10.1182/blood.V108.11.691.691

Published: 2006

Journal Articles

Early Results from a Phase II Study of Lenalidomide Monotherapy in Relapsed/Refractory Indolent Non-Hodgkin’s Lymphoma.

Thomas E. Witzig, MD, Julie M. Vose, MD, Henry P. Kaplan, MD, Jeffrey Lee Wolf, MD, Dennis Pietronigro, PhD, Kenichi Takeshita, MD, Annette Ervin-Haynes, DO, Jerome B. Zeldis, MD, PhD, Peter H. Wiernik, MD

Blood (2006) 108 (11): 2482.

https://doi.org/10.1182/blood.V108.11.2482.2482

Published: 2006

Journal Articles

High Dose of Rituximab in B-Cell Malignancies.

Vladimir Hugec, MD, Doru T. Alexandrescu, MD, Yukiko Oe, MD, Elisabeth M. Paietta, PhD, Peter H. Wiernik, MD

Blood (2005) 106 (11): 5034.

https://doi.org/10.1182/blood.V106.11.5034.5034

Published: 2005

NARROW

Integrated DNA/RNA Profiling for Somatic Alterations in Adult B-Cell ALL

ETV6 Is An Early T-Cell Progenitor (ETP) Specific Tumor Suppressor Gene in Adult T-ALL

Single-Agent Rituximab in Treatment-Refractory or Poor Prognosis Patients with Chronic Lymphocytic Leukemia.

Standard Consolidation/Maintenance Chemotherapy Is Consistently Superior to a Single Autologous Transplant for Adult Patients with Acute Lymphoblastic Leukemia: Results of the International ALL Trial (MRC UKALL XII/ECOG E2993)

Treatment-Related Mortality and Relapse Rate from Time of Initiation of Post-Remission Therapy for Patients Receiving Allogeneic Transplantation, Autologous Transplantation or Intensive Chemotherapy: A Report from the Eastern Cooperative Oncology Group (ECOG)

Implications for the Use of Monoclonal Antibodies in Future Adult ALL Trials: Analysis of Antigen Expression in 505 B-Lineage (B-Lin) ALL Patients (pts) on the MRC UKALLXII/ECOG2993 Intergroup Trial.

The Pitfalls of Early Publication of Data in Acute Myeloid Leukemia: A Report from the Eastern Cooperative Oncology Group (ECOG).

Treatment Type Determines Gene Expression Changes from Pretreatment (PTx) to Relapse (Rel) in Acute Promyelocytic Leukemia (APL).

Continued Late Conversion to Complete Remission (CR/CRu) and Durability of Remission (DUR) in Pts with B-Cell Follicular Lymphoma (FL) Treated with Rituximab Followed by Mitumprotimut-T (Id-KLH, FavId®) Active Immunotherapy.

Initial Results from an International Study in Relapsed/Refractory Aggressive Non-Hodgkin’s Lymphoma To Confirm the Activity, Safety and Criteria for Predicting Response to Lenalidomide Monotherapy.

Results from a Phase II Study of Lenalidomide Oral Monotherapy in Relapsed/Refractory Indolent Non-Hodgkin’s Lymphoma.

Lenalidomide Response in Relapsed/Refractory Diffuse Large B-Cell Non-Hodgkin’s Lymphoma.

Lenalidomide Response in Relapsed/Refractory Aggressive Non-Hodgkin’s Lymphoma Is Related to Tumor Burden and Time from Rituximab Treatment.

Preliminary Results from a Phase II Study of Lenalidomide Monotherapy in Relapsed/Refractory Aggressive Non-Hodgkin’s Lymphoma.

KLHDC8B Is a Novel, Mitotically-Regulated Classical Hodgkin’s Lymphoma Candidate Susceptibility Gene.

Common Gene Expression Changes in Matched Pretreatment and Relapse Samples from Eastern Cooperative Oncology Group Acute Promyelocytic Leukemia (APL) Patients Treated on the Chemotherapy (C) or All- Trans Retinoic Acid (ATRA)-Containing (A) Randomization Arms of Protocol E2491.

Active Immunotherapy with FavId® (Id/KLH) Following Rituximab Induction: Long-Term Follow-Up of Response Rate Improvement (RRI) and Disease Progression in Follicular Lymphoma Patients (pts).

Early Results from a Phase II Study of Lenalidomide Monotherapy in Relapsed/Refractory Indolent Non-Hodgkin’s Lymphoma.

High Dose of Rituximab in B-Cell Malignancies.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only